Can Exogenous Ketone Supplementation Compensate for Glucose Hypometabolism and Improve Cognitive Processing Speed in Veterans With Prediabetes?
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Regional brain glucose uptake
研究概览
简要总结
Brief Summary
The goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed.
The main questions it aims to answer are:
Do older adults with prediabetes have lower brain glucose uptake and slower cognitive processing speed compared to those with normal glucose levels?
Does a single dose of an exogenous ketone monoester supplement improve cognitive processing speed and brain glucose uptake?
Researchers will compare older adults with prediabetes to older adults with normal glucose levels to determine whether differences exist in brain glucose metabolism and cognitive performance. In a subset of participants, researchers will also compare brain and cognitive outcomes before and after consuming a ketone monoester supplement (DeltaG, Oxford, England).
Participants will:
Complete metabolic testing to determine glucose status
Undergo brain imaging using fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18FDG-PET/MRI) while performing a cognitive processing speed task
Consume a single dose of a commercially available ketone monoester supplement during one study visit
Complete cognitive testing during imaging to measure processing speed and brain activity
The results of this study will help determine whether early metabolic dysfunction is linked to reduced brain energy use and whether ketones can temporarily support brain function in individuals at risk for dementia.
详细描述
Metabolic dysfunction and impaired brain energy metabolism are increasingly recognized as early contributors to cognitive decline and dementia risk. Type 2 diabetes is a well-established risk factor for cognitive impairment; however, less is known about whether cerebral metabolic alterations are already present during the prediabetes stage, prior to clinically apparent cognitive symptoms. Prediabetes is characterized by impaired glucose regulation and early insulin resistance, both of which may reduce the efficiency of glucose transport and utilization in the brain. Because glucose is the brain's primary fuel under usual dietary conditions, even subtle reductions in cerebral glucose uptake may create a relative energy deficit that affects neural efficiency and cognitive performance.
Reductions in cerebral glucose metabolism have been observed years before the onset of dementia symptoms. These changes are particularly evident in frontal and temporoparietal regions that support higher-order cognitive functions, including processing speed. Cognitive processing speed is one of the earliest cognitive domains to decline in both metabolic disease and neurodegenerative conditions and is closely linked to functional independence in older adults. Identifying early metabolic and neural alterations in individuals with prediabetes may therefore provide insight into mechanisms linking metabolic dysfunction to later dementia risk.
This study uses hybrid fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18F-FDG PET/MRI) to quantify regional brain glucose uptake while participants perform a cognitive processing speed task during the imaging session. Fluorodeoxyglucose (FDG) is a radiolabeled glucose analog that allows measurement of tissue glucose uptake as an index of metabolic activity. Simultaneous magnetic resonance imaging (MRI), including functional MRI (fMRI), provides complementary measures of neural activation and network engagement during task performance. This multimodal approach allows assessment of neural efficiency, defined as cognitive task performance relative to regional glucose uptake and blood oxygen level-dependent (BOLD) signal changes.
The first objective of the study is to determine whether older adults with prediabetes exhibit reduced regional brain glucose uptake and slower cognitive processing speed compared to metabolically normal older adults. Metabolic status will be characterized using standardized clinical testing to define glycemic phenotype. The primary neural outcome is regional FDG uptake during task performance, and the primary cognitive outcome is processing speed performance acquired during the scan.
The second objective is to determine whether acute elevation of circulating ketone bodies through ingestion of an exogenous ketone monoester (DeltaG, Oxford, England) modifies cognitive performance and cerebral glucose uptake. Ketone bodies, including beta-hydroxybutyrate, serve as an alternative fuel for the brain and can be utilized even when glucose metabolism is impaired. Acute ketone supplementation increases circulating ketone concentrations without requiring prolonged dietary modification. This study evaluates whether providing an alternative metabolic substrate acutely influences neural efficiency and cognitive processing speed in individuals at risk for metabolic-related cognitive decline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 60 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 60 to 75 years
- •Able to provide written informed consent
- •Fluent in English
- •No diagnosed cognitive impairment or dementia
- •Classified as either:
- •Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)
- •Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging
- •Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging
排除标准
- •Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder
- •Diagnosis of type 1 diabetes or type 2 diabetes
- •Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)
- •History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness >30 minutes, epilepsy, multiple sclerosis)
- •Major psychiatric disorder not stable on treatment
- •Uncontrolled hypertension or significant cardiovascular disease
- •Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism
- •Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)
研究组 & 干预措施
Ketone
干预措施: Ketone Monoester (KE) (Dietary Supplement)
Placebo
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Regional brain glucose uptake
时间窗: Two visits (placebo and ketone condition in random order) will take place within 4 weeks of enrollment. Main outcome is change in cerebral glucose uptake between placebo and ketone conditions.
Regional brain glucose uptake measured by fluorodeoxyglucose F18 positron emission tomography. The primary outcome is regional cerebral glucose uptake quantified using fluorodeoxyglucose F18 positron emission tomography integrated with magnetic resonance imaging. Glucose uptake will be assessed in prespecified frontal and temporoparietal regions implicated in early metabolic and cognitive decline. Uptake values will be expressed as standardized uptake value ratios to allow regional comparison across participants. This outcome is used to determine (1) whether older adults with prediabetes exhibit reduced task-related brain glucose uptake compared to metabolically normal older adults, and (2) whether acute ketone monoester ingestion alters regional glucose uptake during cognitive task performance.
次要结局
未报告次要终点
研究者
Katherine Sweatt
Scientist I
University of Alabama at Birmingham
